Global Cell Expansion Market Overview
The key driver impacting the cell expansion market is the increasing incidence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. For instance, The National Center for Biotechnology Information (NCBI) report presents that almost one in three adults suffers from multiple chronic conditions (MCCs). The WHO report shows that chronic disease accounts for 60% of the worldwide disease burden in 2020. Globally cancer is responsible for the second most leading cause of death, and it accounted for 9.6 million deaths in 2018. Similarly, diabetes is also one of the most prevalent diseases globally. As per the International Diabetic Federation (IDF), In 2019, over 463 million adults (20-79 years) were living with diabetes, and it is projected to reach 700 million by 2045. Cell expansion techniques are widely used in the research and development of medicines, vaccines, antibiotics, and therapeutics used for treating such diseases. The escalating incidence of diseases such as diabetes and cancer has created a need for extensive research to develop new treatment options. Moreover, the increasing focus on personalized medicine contributes to the cell expansion market growth in the coming years.
According to Value Market Research, the global cell expansion market size was valued at around USD 15000 million in 2020 and is estimated to grow at a CAGR of about 15% during the forecast period 2021 to 2027.
The government investments for cell-based research globally are estimated to augment cell expansion needs in the forecast period. For instance, as per the Australian Department Of Health, 2021 report, the stem cell research funding program known as the stem cell therapies mission will spend $150 million over nine years to develop innovative, safe, and effective treatments that are reachable to all Australians who require them. In October 2019, the Medical Technology Enterprise Consortium (MTEC) and the FDA jointly granted a fund of USD 5.3 million to the U.S. Southwest Research Institute (SwRI). The SwRI spends these funds to propagate cells for personalized regenerative medicine development. In 2019, AICR (American Institute for cancer research) had joined one voice against cancer (OVAC). It is an agreement of cancer-fighting organizations with the aim of augmenting funding for federal cancer research programs. NIH was finally funded around $41.46 billion, with NCI (national cancer institute) got a fund of $6.44 billion. However, Ethical concerns regarding research in cell biology may hamper the market in the long run. Also, the Challenges in the governance of cell-based therapies negatively impact the market. The current industry trends, such as the technological advancements in the field of cell culturing and growing trends of regenerative medicine, tissue engineering, regenerative medicine, and biopharmaceuticals, are expected to offer new market opportunities for the key players.
The cell expansion market is vast, with many local and global players. The cell expansion market is extensive, with many international and regional players. The key market leaders follow several strategies to improve their market statuses, such as extending product portfolio, amalgamation, contracts, acquisitions, product upgrades to enlarge their market share across the globe. In June 2019, Demcon acquired a stake in the stem cell-based therapy equipment manufacturer Scinus Cell Expansion B.V. This acquisition enables Scinus to enlarge its business in the market of stem cell therapy. The important players studied in the report are Thermo Fisher Scientific, Inc., Corning, Inc., Merck KGaA, Becton, Dickinson and Company, Sartorius AG, upcyte technologies GmbH.,GE Healthcare, STEMCELL Technologies, Inc., Miltenyi Biotec, Terumo Bct, Inc., Takara Bio, Inc., and Trinova Biochem GmbH.
In this research report, the cell expansion market is segmented by product, cell type, application, end-use, and region.
Analysis by Product
By product, the report is categorized into consumables and instruments. Consumables dominate the product segment with over 45% share in 2020. It is due to the high availability of a broad range of commercial media and reagent products made to specific types of cells. Moreover, these products are ready-to-use, convenient, and are also available as serum-free formulations, thus contributes to the consumables segment growth in the forecast period.
Analysis by Cell Type
By cell type, the report is categorized into mammalian, human, stem cells (SCS), adult scs, embryonic SCS, induced pluripotent SCs, differentiated cells, animal, microbial, and others. Mammalian cells dominate the cell type segment with over 55% share in 2020. It is due to the high preference for these types of culture systems in complex protein therapeutics production. Most of the biopharmaceuticals, including monoclonal antibodies, thrombolytic, specific interferon’s, and various therapeutic enzymes, are made utilizing these culture systems. Moreover, these systems are pharmacokinetically and functionally relevant to post-translational modifications in humans creates a high demand for mammalian cells in the irrigation process.
Analysis by Application:
By application, the report is categorized into tissue culture & engineering, biopharmaceuticals, stem cell research, vaccine production, drug development, gene therapy, cancer research, stem cell research, and others. Biopharmaceutical dominates the application segment with over 23% share in 2020. It is due to the increasing approvals of biopharmaceutical products in the precedent few years. Moreover, the entrance of new biopharmaceutical companies and the abundance of bio-processing technologies contribute to the increased market demand from the biopharmaceuticals sector in the forecast period.
Analysis by End-Use:
By application, the report is categorized into biopharmaceutical & biotechnology companies, research institutes, cell banks, and others. Biotechnology& biopharmaceutical companies dominate the application segment with over 48% share in 2020. It is due to the expanding horizon of cell-based therapeutics in the healthcare sector. Moreover, the growing popularity of cellular-based therapies in regenerative medicine with continual enhancement in injectable cell delivery systems for several clinical applications contributes to the increased market demand from the—biotechnology & biopharmaceutical sector in the forecast period.
Analysis by Region:
In the regional outlook of the global Cell expansion market, the North America region dominates globally with a 40% market share in the forecast period. It is due to the growing funding initiatives by the U.S and Canadian government agencies, which has to speed up the research related to stem cells and the development of cellular therapy products and regenerative medicine. Moreover, growing awareness regarding advanced treatment methods, the strong presence of industry players, and the rising geriatric population contribute to market growth across North America.
Market Segmentation covered in the Report:
By Cell Type
- Consumables (Reagents, Media, & Serum, Other Consumables)
- Culture Flasks and Accessories (Tissue Culture Flasks, Bioreactor Accessories, Other Culture Flasks and Accessories)
- Instruments (Automated Cell Expansion Systems, Cell Counters, Centrifuges, Bioreactors, Other Instruments)
- Stem Cells (SCs)
- Adult SCs
- Embryonic SCs
- Induced Pluripotent SCs
- Differentiated Cells
- Tissue Culture & Engineering
- Vaccine Production
- Drug Development
- Gene Therapy
- Cancer Research
- Stem Cell Research
- Biopharmaceutical & Biotechnology Companies
- Research Institutes
- Cell Banks
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.